 Seagen Inc NASDAQ: SGEN and Genmab AS NASDAQ: GMAB have interim data from two Phase 1b2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin TV in recurrent or metastatic cervical cancer. 